Annual CFF
$116.93 M
+$19.80 M+20.38%
31 December 2023
Summary:
UroGen Pharma annual cash flow from financing activities is currently $116.93 million, with the most recent change of +$19.80 million (+20.38%) on 31 December 2023. During the last 3 years, it has risen by +$100.40 million (+607.51%). URGN annual CFF is now -29.24% below its all-time high of $165.25 million, reached on 31 December 2019.URGN Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$39.61 M
-$60.68 M-60.51%
30 September 2024
Summary:
UroGen Pharma quarterly cash flow from financing activities is currently $39.61 million, with the most recent change of -$60.68 million (-60.51%) on 30 September 2024. Over the past year, it has dropped by -$76.47 million (-65.88%). URGN quarterly CFF is now -75.78% below its all-time high of $163.51 million, reached on 31 March 2019.URGN Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$194.59 M
-$76.47 M-28.21%
30 September 2024
Summary:
UroGen Pharma TTM cash flow from financing activities is currently $194.59 million, with the most recent change of -$76.47 million (-28.21%) on 30 September 2024. Over the past year, it has increased by +$52.33 million (+36.78%). URGN TTM CFF is now -28.21% below its all-time high of $271.06 million, reached on 30 June 2024.URGN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
URGN Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +20.4% | -65.9% | +36.8% |
| 3 y3 years | +607.5% | +10000.0% | +168.7% |
| 5 y5 years | +76.0% | +3417.4% | +16.4% |
URGN Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +607.5% | -65.9% | >+9999.0% | -28.2% | +619.0% |
| 5 y | 5 years | -29.2% | +607.5% | -65.9% | >+9999.0% | -28.2% | >+9999.0% |
| alltime | all time | -29.2% | >+9999.0% | -75.8% | >+9999.0% | -28.2% | >+9999.0% |
UroGen Pharma Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $39.61 M(-60.5%) | $194.59 M(-28.2%) |
| June 2024 | - | $100.28 M(+83.5%) | $271.06 M(+58.6%) |
| Mar 2024 | - | $54.66 M(>+9900.0%) | $170.92 M(+46.2%) |
| Dec 2023 | $116.93 M(+20.4%) | $40.00 K(-100.0%) | $116.93 M(-17.8%) |
| Sept 2023 | - | $116.08 M(>+9900.0%) | $142.26 M(+421.4%) |
| June 2023 | - | $143.00 K(-78.7%) | $27.28 M(+0.8%) |
| Mar 2023 | - | $671.00 K(-97.4%) | $27.06 M(-72.1%) |
| Dec 2022 | $97.13 M(+34.3%) | $25.37 M(+2204.1%) | $97.13 M(+35.4%) |
| Sept 2022 | - | $1.10 M(-1529.9%) | $71.73 M(+1.8%) |
| June 2022 | - | -$77.00 K(-100.1%) | $70.47 M(-50.7%) |
| Mar 2022 | - | $70.74 M(<-9900.0%) | $143.06 M(+97.8%) |
| Dec 2021 | $72.32 M(+337.6%) | -$32.00 K(-81.0%) | $72.32 M(-0.2%) |
| Sept 2021 | - | -$168.00 K(-100.2%) | $72.43 M(-0.3%) |
| June 2021 | - | $72.52 M(>+9900.0%) | $72.66 M(+341.9%) |
| Mar 2021 | - | $4000.00(-94.9%) | $16.44 M(-0.5%) |
| Dec 2020 | $16.53 M | $78.00 K(+27.9%) | $16.53 M(-1.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | $61.00 K(-99.6%) | $16.69 M(-6.0%) |
| June 2020 | - | $16.30 M(>+9900.0%) | $17.76 M(+868.3%) |
| Mar 2020 | - | $90.00 K(-63.3%) | $1.83 M(-98.9%) |
| Dec 2019 | $165.25 M(+148.8%) | $245.00 K(-78.2%) | $165.25 M(-1.2%) |
| Sept 2019 | - | $1.13 M(+201.9%) | $167.21 M(+0.7%) |
| June 2019 | - | $373.00 K(-99.8%) | $166.06 M(+0.2%) |
| Mar 2019 | - | $163.51 M(+7332.1%) | $165.67 M(+149.4%) |
| Dec 2018 | $66.42 M(+7.9%) | $2.20 M(<-9900.0%) | $66.42 M(+3.5%) |
| Sept 2018 | - | -$14.00 K(-33.3%) | $64.17 M(+0.6%) |
| June 2018 | - | -$21.00 K(-100.0%) | $63.78 M(-49.4%) |
| Mar 2018 | - | $64.26 M(<-9900.0%) | $125.95 M(+104.5%) |
| Dec 2017 | $61.59 M(<-9900.0%) | -$56.00 K(-86.0%) | $61.59 M(-0.1%) |
| Sept 2017 | - | -$399.00 K(-100.6%) | $61.64 M(-0.6%) |
| June 2017 | - | $62.15 M(<-9900.0%) | $62.04 M(<-9900.0%) |
| Mar 2017 | - | -$108.00 K | -$108.00 K |
| Dec 2016 | -$9000.00(-100.0%) | - | - |
| Dec 2015 | $21.58 M | - | - |
FAQ
- What is UroGen Pharma annual cash flow from financing activities?
- What is the all time high annual CFF for UroGen Pharma?
- What is UroGen Pharma annual CFF year-on-year change?
- What is UroGen Pharma quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for UroGen Pharma?
- What is UroGen Pharma quarterly CFF year-on-year change?
- What is UroGen Pharma TTM cash flow from financing activities?
- What is the all time high TTM CFF for UroGen Pharma?
- What is UroGen Pharma TTM CFF year-on-year change?
What is UroGen Pharma annual cash flow from financing activities?
The current annual CFF of URGN is $116.93 M
What is the all time high annual CFF for UroGen Pharma?
UroGen Pharma all-time high annual cash flow from financing activities is $165.25 M
What is UroGen Pharma annual CFF year-on-year change?
Over the past year, URGN annual cash flow from financing activities has changed by +$19.80 M (+20.38%)
What is UroGen Pharma quarterly cash flow from financing activities?
The current quarterly CFF of URGN is $39.61 M
What is the all time high quarterly CFF for UroGen Pharma?
UroGen Pharma all-time high quarterly cash flow from financing activities is $163.51 M
What is UroGen Pharma quarterly CFF year-on-year change?
Over the past year, URGN quarterly cash flow from financing activities has changed by -$76.47 M (-65.88%)
What is UroGen Pharma TTM cash flow from financing activities?
The current TTM CFF of URGN is $194.59 M
What is the all time high TTM CFF for UroGen Pharma?
UroGen Pharma all-time high TTM cash flow from financing activities is $271.06 M
What is UroGen Pharma TTM CFF year-on-year change?
Over the past year, URGN TTM cash flow from financing activities has changed by +$52.33 M (+36.78%)